Proceedings of the 3rd International Conference on Modern Medicine and Global Health
DOI: 10.54254/2753-8818/2025.24198

Optimising Parkinson's Disease Management: A Comparative Analysis of Levodopa and Dopamine Agonists

Ava Guarnotta

Pomfret School, Pomfret, USA
aguarnotta.26@pomfret.org

Abstract: Motor and non-motor symptoms are hallmarks of Parkinson's disease (PD), a chronic, progressive neurodegenerative illness caused by the decline of dopamine-producing neurones in the substantia nigra. Although the exact cause is still unknown, environmental variables like pesticide exposure and genetic alterations (such as SNCA, LRRK2, and PARK7) are involved in its development. Tremors, bradykinesia, stiffness, and postural instability are the hallmark motor symptoms that are caused by a dopamine deficit in the basal ganglia. Quality of life is impacted by non-motor symptoms such as mood problems, sleep disruptions, and cognitive deterioration. By restoring dopamine levels in the brain, Levodopa efficiently treats motor symptoms and is still the gold standard for treating Parkinson's disease. When combined with carbidopa to increase delivery and reduce side effects, Levodopa dramatically enhances motor function, particularly in the early and middle stages of the disease. However, problems, including dyskinesia and motor irregularities, are linked to prolonged use. Another treatment option is provided by dopamine agonists, which directly activate dopamine receptors, especially in younger or early-stage PD patients. They reduce the risk of early dyskinesia by delaying Levodopa and providing long-lasting symptom alleviation, although less effective than Levodopa. They do, however, have an increased risk of behavioural and cognitive adverse effects, including impulse control issues and hallucinations. Combination therapy maximises symptom management by utilising the advantages of both levodopa and dopamine agonists, but it necessitates close observation. Treatment plans must change as PD worsens to strike a balance between effectiveness and adverse effects. Future studies on sophisticated medication regimens and neuroprotective therapies have the potential to improve long-term results in the treatment of Parkinson's disease.

Keywords: Parkinson's disease (PD), Levodopa, Dopamine agonists

1. Introduction

Parkinson's disease (PD) is a neurological illness that affects predominantly motor function and is chronic and progressive. It happens when the brain's dopamine-producing neurons are dying off [1]. Although the precise aetiology of Parkinson's disease (PD) remains unclear, genetic and environmental factors are thought to contribute to the disease's development. Specific genetic mutations in the SNCA, LRRK2, and PARK7 genes, for example, have been associated with 10–15% of instances of Parkinson's disease (PD) and have the potential to cause early-onset PD or increase vulnerability [2]. Environmental variables are also linked to an increased risk of Parkinson's disease (PD), such as prolonged exposure to pesticides, specific heavy metals, and head trauma [3].

DOI: 10.54254/2753-8818/2025.24198

The deficiency of dopamine in the basal ganglia, a part of the brain essential for controlling voluntary movement, is the primary cause of Parkinson's disease (PD). The midbrain region, known as the substantia nigra is where dopamine is made. Dopamine levels in the basal ganglia are significantly reduced in Parkinson's disease (PD) due to a gradual loss of dopaminergic neurones in the substantia nigra [4]. The motor symptoms specific to the condition are brought on by this depletion, which impairs the brain's capacity to regulate movement. With Parkinson's disease (PD), there is a slow and irreversible loss of neurons, and as the condition worsens, other neurotransmitter systems like norepinephrine and serotonin are also impacted. Alpha-synuclein proteins misfolded accumulate in the brain to form Lewy bodies, a prominent pathogenic characteristic of Parkinson's disease (PD). The aberrant protein clumps are a contributing factor to the Parkinson's disease neurodegeneration [5].

There are two groups of Parkinson's disease symptoms: motor and non-motor. The most obvious symptoms are movement-related, such as bradykinesia (slowness of movement), stiffness, tremors, and postural instability. Tremors, frequently the first symptom, usually affect the hands or fingers and are easiest to see when the patient is not moving. Increased muscular stiffness is called rigidity, which can hurt and restrict the range of motion [6]. Bradykinesia is a characteristic symptom that slows physical activity, making initiating and executing movements difficult. Later in the disease, postural instability reduces balance and coordination, which raises the risk of falls [7].

Several non-motor symptoms are also linked to Parkinson's disease (PD), which can have a significant impact on a patient's quality of life in addition to motor symptoms. In the later stages of Parkinson's disease (PD), cognitive decline is prevalent, and some individuals develop dementia from the disease, which affects memory, decision-making, and problem-solving skills. Mood disorders, including anxiety, depression, and apathy, are also common; these may be brought on by changes in brain chemistry as well as the difficulties of managing a long-term medical condition. Insomnia, excessive daytime sleepiness, and REM sleep behaviour disorder are examples of sleep abnormalities that are common in PD patients and can exacerbate their illness [8].

The main clinical factor used to diagnose Parkinson's disease (PD) is the existence of motor symptoms. Neurologists look for at least two cardinal signs to diagnose tremors, bradykinesia, stiffness, and postural instability. Even though there isn't a single test that can diagnose Parkinson's disease (PD), imaging methods like dopamine transporter scans can help by showing how much dopamine is active in the brain [9]. The Hoehn and Yahr scale, which categorises the disease into five phases according to the severity of symptoms, is frequently used to track the progression of Parkinson's disease. Stage 1 consists of mild, unilateral symptoms with minor impairment, whereas Stage 5 is characterised by significant disability and bedridden or wheelchair-bound status. Parkinson's disease is progressive and irreversible; hence, while therapies are available to manage symptoms, there is presently no known cure, and the condition continues to pose a significant medical challenge [10].

2. Levodopa

Levodopa is still the most extensively used medication to treat Parkinson's disease (PD) and is considered the best option for treating motor symptoms. It has been used for decades to treat Parkinson's disease (PD)-related bradykinesia, stiffness, and tremors. Levodopa acts by restoring dopamine, a vital neurotransmitter that is depleted as the disease worsens and provides patients at different stages of the disease with respite [11].

Levodopa acts by treating the leading cause of Parkinson's disease, which is the death of dopamine-producing neurons in the brain region of the substantia nigra, which controls movement. Dopamine cannot pass across the blood-brain barrier by itself, so taking dopamine supplements directly won't work. Levodopa, a chemical before dopamine, can overcome this barrier. Once in the brain, the

DOI: 10.54254/2753-8818/2025.24198

enzyme aromatic L-amino acid decarboxylase (AADC) transforms levodopa into dopamine, hence raising dopamine levels in the basal ganglia, the region of the brain responsible for controlling movement [12].

The brain's process of converting levodopa into dopamine is what makes it so successful in treating Parkinson's disease (PD) motor symptoms. Levodopa helps individuals move better by momentarily restoring dopamine levels. This helps to lessen symptoms, including tremors, muscle stiffness, and slow movement (bradykinesia). The increasing loss of dopaminergic neurons is compensated for by an increase in dopamine availability, which gives the brain some control over voluntary actions again [13].

Levodopa significantly improves bradykinesia, stiffness, and tremors. It is especially helpful in lowering motor symptoms in the early to mid-stages of Parkinson's disease. Even after years of illness development, clinical investigations consistently demonstrate its effectiveness in helping patients restore motor function. Levodopa is usually used with carbidopa to increase efficacy and lessen unwanted effects. Carbidopa stops levodopa from prematurely converting to dopamine outside the brain. By maximising levodopa's delivery to the brain, this combination minimises adverse effects like nausea while delivering long-lasting symptom alleviation [12].

Long-term use of levodopa is associated with side effects such as dyskinesia, which involves involuntary, erratic movements that typically develop after years of treatment due to fluctuating dopamine levels. Another common complication is motor fluctuations, known as the "on-off" phenomenon, where patients alternate between periods of effective symptom control ("on" periods) and the return of motor symptoms ("off" periods). These side effects tend to worsen as the disease progresses, requiring adjustments in treatment strategies [13].

Levodopa remains the most effective treatment for motor symptoms in Parkinson's disease. It is often used as a first-line therapy because it significantly improves quality of life, especially in the early stages. Despite long-term complications like dyskinesia and motor fluctuations, its unmatched efficacy in managing tremors, rigidity, and bradykinesia makes it the cornerstone of PD treatment. As the disease progresses, levodopa may be combined with other medications or treatments, such as deep brain stimulation, but it remains central to managing symptoms throughout the disease course [14].

3. Dopamine agonists

Parkinson's disease (PD) is treated using a family of medications called dopamine agonists, which work by imitating the actions of dopamine, a neurotransmitter that is lacking in PD patients. Dopamine agonists directly activate dopamine receptors, negating the requirement for the brain to manufacture dopamine on its own, in contrast to levodopa, which is converted into dopamine in the brain. Dopamine agonists are a valuable therapy option for Parkinson's disease (PD), especially for younger individuals or those with the disease in its early stages due to their distinct mode of action [15].

Dopamine agonists mimic the effects of dopamine without the need for dopamine to be present by attaching to and activating dopamine receptors in the brain. Since the hallmark of Parkinson's disease is the death of dopamine-producing neurones, these medications make up for the loss by activating dopamine receptors directly in regions of the brain that regulate movement, such as the basal ganglia. Dopamine agonists can aid in the regulation of movement and lessen the motor symptoms linked to Parkinson's disease (PD) by avoiding the brain's process of converting levodopa into dopamine [16].

Dopamine agonists help treat symptoms while avoiding some of the swings associated with levodopa because they may directly activate dopamine receptors, allowing for more constant receptor activation. As a result, dopamine agonists may be helpful in the early stages of the disease as they can alleviate symptoms without requiring the death of neurones to produce dopamine [17].

DOI: 10.54254/2753-8818/2025.24198

Motor symptoms can be effectively managed with dopamine agonists, particularly in the early stages of Parkinson's disease. Even though they are not as strong as levodopa, they have a longer half-life and significantly reduce symptoms, enabling longer-term symptom management. This makes them helpful for postponing the start of levodopa to prevent the long-term problems connected to levodopa, especially in younger individuals. To lessen motor fluctuations, medications like pramipexole and ropinirole are frequently given as monotherapy early in the disease or in conjunction with levodopa later on [18].

Compared to levodopa, dopamine agonists are less likely to cause dyskinesia. Still, they are more likely to cause cognitive and mental side effects, such as delusions, hallucinations, and problems with impulse control (like excessive shopping or gambling). Dizziness, drowsiness, and orthostatic hypotension—sudden dips in blood pressure when standing—are other typical adverse effects. While lowering the dosage can help control these adverse effects, which are frequently dose-related, careful monitoring is necessary to prevent hazards such as daytime drowsiness and reduced performance [19].

Dopamine agonists are crucial in the treatment of Parkinson's disease, particularly for younger patients, since they help postpone the need for levodopa and, consequently, the motor difficulties linked to long-term levodopa usage. In the early stages of the illness, they are frequently used to reduce symptoms and preserve motor function. Dopamine agonists are an essential component of long-term therapy plans because, as the condition worsens, they are commonly used in addition to levodopa to improve overall symptom management and smooth out motor swings [17].

4. Comparison

Parkinson's disease (PD) is primarily treated with two major pharmacological classes: dopamine agonists and levodopa. Each has a unique mode of action, degree of efficacy, and range of adverse effects. Although both are essential to treating the illness, they are frequently utilised in various ways and at different phases based on the patient's symptoms and the disease's course. A comparison of these two therapies reveals the advantages and disadvantages of each in terms of managing Parkinson's disease symptoms [20].

Levodopa is regarded as the gold standard when it comes to effectively treating Parkinson's disease's motor symptoms. It offers better control over motor problems such as bradykinesia, stiffness, and tremors, especially in the middle to late stages of Parkinson's disease. According to clinical research, levodopa provides the most significant gains in motor function, enabling patients to regain independence in their everyday activities [11]. Contrarily, dopamine agonists, especially in the early stages of Parkinson's disease (PD), are less potent than levodopa but beneficial in lowering motor fluctuations and prolonging the "on" periods when symptoms are under control. They are frequently used to postpone the start of levodopa, which may be advantageous for younger people who may develop long-term problems from levodopa sooner as a result of having a more prolonged illness [17].

Dopamine agonists and levodopa have quite different adverse impact profiles. Long-term usage of levodopa is linked to the development of dyskinesia, a condition marked by irregular, uncontrollable movements that get worse with time. It is believed that dyskinesia is caused by fluctuating dopamine levels, which can get worse as a patient's condition worsens and when they take levodopa for more extended periods [21]. Dopamine agonists, on the other hand, are more appealing in the early stages of therapy due to their decreased risk of dyskinesia. On the other hand, dopamine agonists are more likely to have cognitive and mental adverse effects, including impulse control disorders (ICDs), which include excessive shopping, overeating, or gambling [22]. These behaviours can be pretty disruptive, particularly in younger patients, and may necessitate changing the medication's dosage or stopping it altogether.

Both medication types can potentially impair cognitive performance, especially in older individuals. Levodopa, while typically safer from a cognitive perspective, might nonetheless

DOI: 10.54254/2753-8818/2025.24198

aggravate mental loss in people already prone to cognitive impairment [23]. Dopamine agonists are more likely to produce hallucinations and disorientation [24]. Because of this, clinicians must carefully consider the advantages of symptom management concerning the risk of cognitive and mental problems when deciding between the two medications [25].

Early-stage Parkinson's disease (PD) is frequently best treated with dopamine agonists, especially in younger people. Doctors can assist in delaying the onset of dyskinesia caused by levodopa by postponing the drug's administration. This will provide longer-term motor control with fewer side effects [19]. But when the disease progresses, levodopa replaces other medications as the cornerstone of care because of its unparalleled capacity to manage severe motor symptoms. When Parkinson's disease (PD) progresses, and patients encounter more severe movement impairments, levodopa works better than dopamine agonists to enhance everyday functioning and quality of life [13].

Levodopa and dopamine agonists are frequently used in combination to provide the best symptom management possible as Parkinson's disease advances. By combining the two, patients can take advantage of Levodopa's enhanced motor control and dopamine agonists' ability to lessen motor fluctuations and increase the length of "on" periods [26]. By reducing the swings between "on" and "off" times, this strategy can facilitate better illness management. However, combined treatment also makes adverse effects more complicated. The addition of dopamine agonists can increase the risk of mental symptoms such as hallucinations or impulse control difficulties, even though dyskinesia is still a worry with levodopa. As a result, close observation is necessary to tailor the drug balance to the individual requirements of each patient [15].

In conclusion, levodopa and dopamine agonists work in tandem to treat Parkinson's disease. Although levodopa provides better control of motor symptoms, particularly in more advanced stages, there is a greater chance of long-term side effects such as dyskinesia. Although less powerful, dopamine agonists can lessen motor fluctuations and postpone the need for levodopa, making them helpful in therapy's first stages. Combination treatment is frequently used to maximise the benefits of both drugs while reducing the hazards connected with the long-term use of each one separately. This gives patients the most thorough symptom management possible.

5. Conclusion

Although levodopa and dopamine agonists are equally crucial for treating Parkinson's disease, they are not interchangeable in terms of efficacy, side effects, or timing of administration. The most effective treatment for motor symptoms is levodopa, especially when the condition is advanced. However, long-term levodopa usage is linked to dyskinesia and motor fluctuations [27]. On the other hand, dopamine agonists have a longer duration of action and a decreased risk of dyskinesia, but they are less efficient in regulating motor symptoms [28]. However, they can be challenging for some individuals, especially the elderly, as they have a higher likelihood of causing impulse control issues and cognitive adverse effects.

One of these two therapies may be chosen depending on the patient's age, illness stage, and unique pharmaceutical reaction. Levodopa becomes the go-to medication in advanced illnesses as motor symptoms deteriorate. However, dopamine agonists are frequently favoured in younger people or those with early-stage Parkinson's disease to postpone the need for it. Combination treatment reduces symptoms more effectively, but it must be carefully managed to balance its advantages and disadvantages [29].

Dopamine agonists and levodopa may serve as a platform for future medicines that could improve therapy. Better methods for handling the long-term negative effects of existing drugs, as well as neuroprotective therapies that may halt the course of the illness, are becoming increasingly necessary. Further research is required to enhance the quality of life for those suffering from Parkinson's disease.

DOI: 10.54254/2753-8818/2025.24198

References

[1] Mandybur, George, and Maureen Gartner. "Parkinson's disease (PD)." Mayfield Brain & Spine. https://mayfieldclinic.com/pe-pd.htm#:~:text=Overview,stiffness%2C%20and%20balance%20problems%20occur.

[2] Nuytemans, Karen, Jessie Theuns, Marc Cruts, and Christine Van Broeckhoven. "Genetic Etiology of Parkinson Disease Associated with Mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 Genes: A Mutation Update." Human Mutation 31, no. 7 (2010): 763-80. https://doi.org/10.1002/humu.21277.

[3] "Can Environmental Toxins Cause Parkinson's Disease?" John Hopkins Medicine. https://www.hopkinsmedicine.org/health/conditions-and-diseases/parkinsons-disease/can-environmental-toxins-cause-parkinson-disease.

[4] Sonne, James, Vamsi Reddy, and Morris R. Beato. "Neuroanatomy, Substantia Nigra." National Library of Medicine. Last modified September 10, 2024. https://www.ncbi.nlm.nih.gov/books/NBK536995/.

[5] Mhyre, Timothy R., James T. Boyd, Robert W. Hamill, and Kathleen A. Maguire-Zeiss. "Parkinson's Disease." Subcellular Biochemistry, 2012, 389-455. https://doi.org/10.1007/978-94-007-5416-4_16.

[6] Mayo Clinic Staff. "Parkinson's disease." Mayo Clinic. Last modified September 27, 2024. https://www.mayoclinic.org/diseases-conditions/parkinsons-disease/symptoms-causes/syc-20376055.

[7] Yu, Jun, ed. "Bradykinesia (Slowness of Movement)." Parkinson's Foundation. https://www.parkinson.org/understanding-parkinsons/movement-symptoms/bradykinesia#:~:text=Bradykinesia%20means%20slowness%20of%20movement,Parkinson's%20diagnosis%20to%20be%20considered.

[8] Poewe, W. "Non-motor Symptoms in Parkinson's Disease." European Journal of Neurology 15, no. s1 (2008): 14-20. https://doi.org/10.1111/j.1468-1331.2008.02056.x.

[9] Kouli, Antonina, Kelli M. Torsney, and Wei-Li Kuan. "Chapter 1Parkinson's Disease: Etiology, Neuropathology, and Pathogenesis." National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK536722/.

[10] Stephenson, Ryan O Stephenson. "Modified Hoehn and Yahr Scale." Edited by Buck Christensen. Medscape. https://emedicine.medscape.com/article/2172546-overview?form=fpf.

[11] Gandhi, Kavita R., and Abdolreza Saadabadi. "Levodopa (L-Dopa)." National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK482140/.

[12] Sivanandy, Palanisamy, Tan Choo Leey, Tan Chi Xiang, Tan Chi Ling, Sean Ang Wey Han, Samantha Lia Anak Semilan, and Phoon Kok Hong. "Systematic Review on Parkinson's Disease Medications, Emphasizing on Three Recently Approved Drugs to Control Parkinson's Symptoms." International Journal of Environmental Research and Public Health 19, no. 1 (2021): 364. https://doi.org/10.3390/ijerph19010364.

[13] Levodopa." Parkinson's Foundation. https://www.parkinson.org/living-with-parkinsons/treatment/prescription-medications/levodopa.

[14] Tolosa, Eduardo, Maria J. Martí, Francesc Valldeoriola, and José L. Molinuevo. "History of Levodopa and Dopamine Agonists in Parkinson's Disease Treatment." Neurology 50, no. 6_suppl_6 (1998). https://doi.org/10.1212/wnl.50.6_suppl_6.s2.

[15] Choi, Jaehwa, and Kristen Ashley Horner. "Dopamine Agonists." National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK551686/.

[16] "Dopamine Agonists." Cleveland Clinic. https://my.clevelandclinic.org/health/treatments/24958-dopamine-agonists.

[17] Pringsheim, Tamara, Gregory S. Day, Don B. Smith, Alex Rae-Grant, Nicole Licking, Melissa J. Armstrong, Rob M.A de Bie, Emmanuel Roze, Janis M. Miyasaki, Robert A. Hauser, Alberto J. Espay, Justin P. Martello, Julie A. Gurwell, Lori Billinghurst, Kelly Sulilvan, Michael S. Fitts, Nicolas Cothros, Deborah A. Hall, Miriam Rafferty, Lynn Hagerbrant, Tara Hastings, Mary Dolan O"Brien, Heather Silsbee, Gary Gronseth, and Anthony E. Lang. "Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary." Neurology. https://www.neurology.org/doi/10.1212/WNL.0000000000012868.

[18] Grall-Bronnec, Marie, Caroline Victorri-Vigneau, Yann Donnio, Juliette Leboucher, Morgane Rousselet, Elsa Thiabaud, Nicolas Zreika, Pascal Derkinderen, and Gaëlle Challet-Bouju. "Dopamine Agonists and Impulse Control Disorders: A Complex Association." Drug Safety 41, no. 1 (2017): 19-75. https://doi.org/10.1007/s40264-017-0590-6.

[19] Pringsheim, Tamara, Gregory S. Day, Don B. Smith, Alex Rae-Grant, Nicole Licking, Melissa J. Armstrong, Rob M.A de Bie, Emmanuel Roze, Janis M. Miyasaki, Robert A. Hauser, Alberto J. Espay, Justin P. Martello, Julie A. Gurwell, Lori Billinghurst, Kelly Sullivan, Michael S. Fitts, Nicholas Cothros, Deborah A. Hall, Miriam Rafferty, Lynn Hagerbrant, Tara Hastings, Mary Dolan O'Brien, Heather Silsbee, Gary Gronseth, Anthony E. Lang, Tamara Pringsheim, Gregory S. Day, DonB Smith, and Alex Rae-Grant. "Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary." Neurology 97, no. 20 (2021): 942-57. https://doi.org/10.1212/wnl.0000000000012868.

DOI: 10.54254/2753-8818/2025.24198

[20] Weiss, Howard D., and Laura Marsh. "Impulse Control Disorders and Compulsive Behaviors Associated with Dopaminergic Therapies in Parkinson's Disease." Neurology Clinical Practice 2, no. 4 (2012): 267-74. https://doi.org/10.1212/cpj.0b013e318278be9b.

[21] Pandey, Sanjay, and Prachaya Srivanitchapoom. "Levodopa-induced Dyskinesia: Clinical Features, Pathophysiology, and Medical Management." Annals of Indian Academy of Neurology 20, no. 3 (2017): 190. https://doi.org/10.4103/aian.aian_239_17.

[22] Weiner, William J. "Initial Treatment of Parkinson's Disease Levodopa or Dopamine Agonists." JAMA Neurology. Last modified December 2004. https://jamanetwork.com/journals/jamaneurology/article-abstract/787192.

[23] Mack, Joel, and Laura Marsh. "Parkinson's Disease: Cognitive Impairment." FOCUS 15, no. 1 (2017): 42-54. https://doi.org/10.1176/appi.focus.20160043.

[24] Ecker, Daniel, Alexander Unrath, Jan Kassubek, and Michael Sabolek. "Dopamine Agonists and Their Risk to Induce Psychotic Episodes in Parkinson's Disease: A Case-control Study." BMC Neurology 9, no. 1 (2009). https://doi.org/10.1186/1471-2377-9-23.

[25] Zhang, Qian, XiangTing Chen, FeiFei Chen, SiYuan Wen, and ChangQing Zhou. "Dopamine Agonists versus Levodopa Monotherapy in Early Parkinson's Disease for the Potential Risks of Motor Complications: A Network Meta-analysis." European Journal of Pharmacology 954 (September 2023): 175884. https://doi.org/10.1016/j.ejphar.2023.175884.

[26] Choi, Jeehwa, and Kristen Ashley Hormer. "Levodopa." National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK551686/.

[27] "Motor Fluctuations and Dyskinesias (diagnosis and Management)." Annals of Indian Academy of Neurology 14, no. Suppl1 (2011): S13-S15. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152175/.

[28] Jing, Xiao-Zhong, Hui-Jia Yang, Reyisha Taximaimaiti, and Xiao-Ping Wang. "Advances in the Therapeutic Use of Non-Ergot Dopamine Agonists in the Treatment of Motor and Non-Motor Symptoms of Parkinson's Disease." Current Neuropharmacology 21, no. 5 (2023): 1224-40. https://doi.org/10.2174/1570159x20666220915091022.

[29] Michel, Martin C., and David Staskin. "Study Designs for Evaluation of Combination Treatment: Focus on Individual Patient Benefit." Biomedicines 10, no. 2 (2022): 270. https://doi.org/10.3390/biomedicines10020270.